Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -1.12.

EBIT: As of FY2025 Q3, the actual value is USD -15.44 M.

Segment Revenue

Medicus Pharma Ltd. reported no revenue from its preclinical programs, as it is considered to be in the R&D stage.

Operational Metrics

• Net Loss: For the three months ended September 30, 2025, the net loss was - $15,981,312, compared to - $2,278,747 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was - $27,259,804, compared to - $7,618,964 for the same period in 2024.
• Operating Expenses: Total operating expenses for the three months ended September 30, 2025 were $15,426,340, compared to $2,334,261 for the same period in 2024. For the nine months ended September 30, 2025, total operating expenses were $26,568,702, compared to $7,595,453 for the same period in 2024.

Cash Flow

• Operating Cash Flow: Net cash used in operating activities for the nine months ended September 30, 2025 was - $16,167,654, compared to - $7,055,679 for the same period in 2024.
• Free Cash Flow: Not explicitly stated, but the net increase in cash and cash equivalents during the period was $4,497,768.

Unique Metrics

• Debentures: On September 17, 2025, a new debenture was issued with a principal amount of $8,000,000 at a discounted price of 90%, with interest accruing at an annual rate of 8%.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue its clinical trials, including SKNJCT-003 and SKNJCT-004, and anticipates increased R&D expenses as these trials progress.
• Non-Core Business: The company completed the acquisition of Antev Limited, acquiring 98.6% of its shares, and plans to integrate Antev’s assets, including Teverelix, into its operations.
• Priority: The company is focused on securing additional capital through public and private equity offerings, debt financings, and strategic alliances to support its ongoing R&D activities and potential commercialization efforts.